Studies have shown that over-expression of NPM can lead to multidrug resistance of ALL, and the engineered recombinant NPM binding protein (NPMBP) can knock out NPM by RNA interference, thus reversing multidrug resistance of leukemia cells (Wang et al., 2015). Here, NPM1 is linked to acute lymphoblastic leukemia.